Company Information

VENUS REMEDIES LTD.

NSE : VENUSREMBSE : 526953ISIN CODE : INE411B01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE327.9523.05 (+7.56 %)
PREV CLOSE ( ) 304.90
OPEN PRICE ( ) 307.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 7289
TODAY'S LOW / HIGH ( )307.00 327.95
52 WK LOW / HIGH ( )160 429.6
NSE325.8520.6 (+6.75 %)
PREV CLOSE( ) 305.25
OPEN PRICE ( ) 306.40
BID PRICE (QTY) 325.85 (1164)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 107324
TODAY'S LOW / HIGH( ) 305.80 329.00
52 WK LOW / HIGH ( )157.95 430
ChairmanPawan Chaudhary
Managing DirectorPawan Chaudhary
Company SecretaryNeha Kodan
Joint Managing DirectorManu Chaudhary
Deputy Managing DirectorPeeyush Jain
Non Executive Independent DirectorGilbert Wenzel
S K Chadha
Navdeep Sud
Savita Gupta
NPS Monga
Whole Time DirectorAshutosh Jain
Akshansh Chaudhary
Incorporation Year : 1989

Registered Office :

Address : S. C. O. 857, C. No. 10,2nd Floor,N A C Manimajra Chandigarh,
Chandigarh-160101 .

Phone : 0172-2561244/5577

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.